ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.
Zacks Investment Research6/18/2026Neutral
ICCC
ImmuCell CorporationNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$96.17M
P/E Ratio
—
EPS
$-0.07
Beta
0.57
52W High
$11.16
52W Low
$4.52
50-Day MA
$9.51
200-Day MA
$7.08
Dividend Yield
—
Profit Margin
-1.82%
Forward P/E
—
PEG Ratio
0.00
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Fundamentals
| Revenue (TTM) | $29.93M |
| Gross Profit (TTM) | $12.75M |
| EBITDA | $5.88M |
| Operating Margin | 19.00% |
| Return on Equity | -1.88% |
| Return on Assets | 4.60% |
| Revenue/Share (TTM) | $3.31 |
| Book Value | $3.22 |
| Price-to-Book | 3.22 |
| Price-to-Sales (TTM) | 3.21 |
| EV/Revenue | 3.336 |
| EV/EBITDA | 40.32 |
| Quarterly Earnings Growth (YoY) | 31.30% |
| Quarterly Revenue Growth (YoY) | 28.40% |
| Shares Outstanding | $9.05M |
| Float | $6.00M |
| % Insiders | 32.13% |
| % Institutions | 21.71% |
Historical Volatility
HV 10-Day
64.14%
HV 20-Day
46.85%
HV 30-Day
50.93%
HV 60-Day
54.30%
HV Rank
45.6%
Volatility is currently expanding
Latest News
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.
Zacks Investment Research5/25/2026Positive
ImmuCell Q1 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported a record first quarter of 2026, with management saying the company's narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever quarter above $10 million in product sales.
MarketBeat5/15/2026Positive
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
Seeking Alpha5/15/2026Neutral
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended March 31, 2026.
GlobeNewsWire5/14/2026Neutral
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended March 31, 2026 after the market closes on Thursday, May 14, 2026. The Company is planning to host a conference call on Friday, May 15, 2026, at 9:00 AM ET to review the unaudited financial results.
GlobeNewsWire5/7/2026Neutral
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell
Goldman Sachs, NextEra Energy and Shopify lead top stock reports, highlighting strong gains, expanding operations and strategic shifts driving growth.
Zacks Investment Research4/22/2026Positive
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors.
GlobeNewsWire4/13/2026Neutral
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026.
GlobeNewsWire4/8/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026